

Source

Biotinylated Monoclonal Anti-FMC63 Antibody, Mouse IgG1, Avitag (Cat. No. FM3-BY54) is expressed from human 293 cells.

Isotype

Mouse IgG1/kappa

Specificity

Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

Labeling

*Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.*

Protein Ratio

Passed as determined by the HABA assay / binding ELISA.

Application

Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression).  
\*The Isotype control (Cat. No. [DNP-BM190](#)) is sold separately and you can follow [this link](#) for product information.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

*Please avoid repeated freeze-thaw cycles.*

This product is stable after storage at:

- 20°C to -70°C for 12 months in lyophilized state;
- 70°C for 12 months under sterile conditions after reconstitution.

Bioactivity-FACS



2e5 of Anti-CD19 CAR-293 cells were stained with 100 µL of 1:50 dilution (2 µL stock solution in 100 µL FACS buffer) Biotinylated Monoclonal Anti-FMC63 Antibody, Mouse IgG1, Avitag (Cat. No. FM3-BY54) and isotype control respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

Background



**Biotinylated Monoclonal Anti-FMC63 Antibody, Mouse IgG1, Avitag™ (Y45)**

Catalog # FM3-BY54



FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

**Clinical and Translational Updates**

